Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer's reported interest in acquiring sickle ... and made an $11.6 billion takeover bid for Biohaven and its migraine therapy Nurtec ODT (rimegepant).

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

After hours: February 21 at 6:53:05 PM EST ...

After hours: February 24 at 5:57:57 p.m. EST ...